The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses

Brendon Y. Chua, Matthew R Olson, Sammy Bedoui, Toshiki Sekiya, Chinn Yi Wong, Stephen J. Turner, David C. Jackson

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We have previously shown that the immunogenicity of protein antigens can be significantly enhanced if electrostatically associated with the Toll-like receptor-2 agonist-based lipopeptide R 4 Pam 2 Cys. The precise mechanisms and effectiveness of the cytotoxic T-lymphocyte (CTL)-mediated response facilitated by this agonist, however, have not been studied. Here we show that priming by dendritic cells (DCs) in the draining lymph nodes of animals vaccinated with antigen delivered using R 4 Pam 2 Cys results in significantly improved T-cell proliferation and induces their differentiation into polyfunctional effector CTLs characterised by granzyme B expression and the ability to secrete interferon-γ, interleukin-2 and tumor necrosis factor-α 7 days after vaccination. After 30 days, frequencies of antigen-specific CD62 low CD127 high (effector memory), CD62 high CD127 high (central memory) and CD43 low CD27 high CD8 + T cells, a phenotype associated with strong recall responses against respiratory infections, are also increased compared with responses obtained with antigens formulated in the adjuvants Alum (alhydrogel) and CFA (complete Freund's adjuvant). The phenotypic changes observed in these mice vaccinated using R 4 Pam 2 Cys further correlated with their ability to recall specific T cells into the lung to mediate the reduction of pulmonary viral titres following challenge with a chimeric influenza virus containing the K b OVA 257-264 epitope compared with animals vaccinated using Alum or CFA. The findings from this study not only demonstrate that better T-cell responses can be elicited using R 4 Pam 2 Cys compared with classically utilised adjuvants but also highlight the potential effectiveness of this lipopeptide-based adjuvant particularly against viral infections that require resolution through cell-mediated immunity.

Original languageEnglish
Pages (from-to)377-383
Number of pages7
JournalImmunology and Cell Biology
Volume92
Issue number4
DOIs
Publication statusPublished - Apr 2014
Externally publishedYes

Keywords

  • Adjuvants
  • anti-viral immunity
  • CD8 T cells
  • TLR2
  • vaccination

Cite this

Chua, Brendon Y. ; Olson, Matthew R ; Bedoui, Sammy ; Sekiya, Toshiki ; Wong, Chinn Yi ; Turner, Stephen J. ; Jackson, David C. / The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses. In: Immunology and Cell Biology. 2014 ; Vol. 92, No. 4. pp. 377-383.
@article{571f661e46584b629deb078b3ce45641,
title = "The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses",
abstract = "We have previously shown that the immunogenicity of protein antigens can be significantly enhanced if electrostatically associated with the Toll-like receptor-2 agonist-based lipopeptide R 4 Pam 2 Cys. The precise mechanisms and effectiveness of the cytotoxic T-lymphocyte (CTL)-mediated response facilitated by this agonist, however, have not been studied. Here we show that priming by dendritic cells (DCs) in the draining lymph nodes of animals vaccinated with antigen delivered using R 4 Pam 2 Cys results in significantly improved T-cell proliferation and induces their differentiation into polyfunctional effector CTLs characterised by granzyme B expression and the ability to secrete interferon-γ, interleukin-2 and tumor necrosis factor-α 7 days after vaccination. After 30 days, frequencies of antigen-specific CD62 low CD127 high (effector memory), CD62 high CD127 high (central memory) and CD43 low CD27 high CD8 + T cells, a phenotype associated with strong recall responses against respiratory infections, are also increased compared with responses obtained with antigens formulated in the adjuvants Alum (alhydrogel) and CFA (complete Freund's adjuvant). The phenotypic changes observed in these mice vaccinated using R 4 Pam 2 Cys further correlated with their ability to recall specific T cells into the lung to mediate the reduction of pulmonary viral titres following challenge with a chimeric influenza virus containing the K b OVA 257-264 epitope compared with animals vaccinated using Alum or CFA. The findings from this study not only demonstrate that better T-cell responses can be elicited using R 4 Pam 2 Cys compared with classically utilised adjuvants but also highlight the potential effectiveness of this lipopeptide-based adjuvant particularly against viral infections that require resolution through cell-mediated immunity.",
keywords = "Adjuvants, anti-viral immunity, CD8 T cells, TLR2, vaccination",
author = "Chua, {Brendon Y.} and Olson, {Matthew R} and Sammy Bedoui and Toshiki Sekiya and Wong, {Chinn Yi} and Turner, {Stephen J.} and Jackson, {David C.}",
year = "2014",
month = "4",
doi = "10.1038/icb.2013.102",
language = "English",
volume = "92",
pages = "377--383",
journal = "Immunology and Cell Biology",
issn = "0818-9641",
publisher = "Nature Publishing Group",
number = "4",

}

The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses. / Chua, Brendon Y.; Olson, Matthew R; Bedoui, Sammy; Sekiya, Toshiki; Wong, Chinn Yi; Turner, Stephen J.; Jackson, David C.

In: Immunology and Cell Biology, Vol. 92, No. 4, 04.2014, p. 377-383.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses

AU - Chua, Brendon Y.

AU - Olson, Matthew R

AU - Bedoui, Sammy

AU - Sekiya, Toshiki

AU - Wong, Chinn Yi

AU - Turner, Stephen J.

AU - Jackson, David C.

PY - 2014/4

Y1 - 2014/4

N2 - We have previously shown that the immunogenicity of protein antigens can be significantly enhanced if electrostatically associated with the Toll-like receptor-2 agonist-based lipopeptide R 4 Pam 2 Cys. The precise mechanisms and effectiveness of the cytotoxic T-lymphocyte (CTL)-mediated response facilitated by this agonist, however, have not been studied. Here we show that priming by dendritic cells (DCs) in the draining lymph nodes of animals vaccinated with antigen delivered using R 4 Pam 2 Cys results in significantly improved T-cell proliferation and induces their differentiation into polyfunctional effector CTLs characterised by granzyme B expression and the ability to secrete interferon-γ, interleukin-2 and tumor necrosis factor-α 7 days after vaccination. After 30 days, frequencies of antigen-specific CD62 low CD127 high (effector memory), CD62 high CD127 high (central memory) and CD43 low CD27 high CD8 + T cells, a phenotype associated with strong recall responses against respiratory infections, are also increased compared with responses obtained with antigens formulated in the adjuvants Alum (alhydrogel) and CFA (complete Freund's adjuvant). The phenotypic changes observed in these mice vaccinated using R 4 Pam 2 Cys further correlated with their ability to recall specific T cells into the lung to mediate the reduction of pulmonary viral titres following challenge with a chimeric influenza virus containing the K b OVA 257-264 epitope compared with animals vaccinated using Alum or CFA. The findings from this study not only demonstrate that better T-cell responses can be elicited using R 4 Pam 2 Cys compared with classically utilised adjuvants but also highlight the potential effectiveness of this lipopeptide-based adjuvant particularly against viral infections that require resolution through cell-mediated immunity.

AB - We have previously shown that the immunogenicity of protein antigens can be significantly enhanced if electrostatically associated with the Toll-like receptor-2 agonist-based lipopeptide R 4 Pam 2 Cys. The precise mechanisms and effectiveness of the cytotoxic T-lymphocyte (CTL)-mediated response facilitated by this agonist, however, have not been studied. Here we show that priming by dendritic cells (DCs) in the draining lymph nodes of animals vaccinated with antigen delivered using R 4 Pam 2 Cys results in significantly improved T-cell proliferation and induces their differentiation into polyfunctional effector CTLs characterised by granzyme B expression and the ability to secrete interferon-γ, interleukin-2 and tumor necrosis factor-α 7 days after vaccination. After 30 days, frequencies of antigen-specific CD62 low CD127 high (effector memory), CD62 high CD127 high (central memory) and CD43 low CD27 high CD8 + T cells, a phenotype associated with strong recall responses against respiratory infections, are also increased compared with responses obtained with antigens formulated in the adjuvants Alum (alhydrogel) and CFA (complete Freund's adjuvant). The phenotypic changes observed in these mice vaccinated using R 4 Pam 2 Cys further correlated with their ability to recall specific T cells into the lung to mediate the reduction of pulmonary viral titres following challenge with a chimeric influenza virus containing the K b OVA 257-264 epitope compared with animals vaccinated using Alum or CFA. The findings from this study not only demonstrate that better T-cell responses can be elicited using R 4 Pam 2 Cys compared with classically utilised adjuvants but also highlight the potential effectiveness of this lipopeptide-based adjuvant particularly against viral infections that require resolution through cell-mediated immunity.

KW - Adjuvants

KW - anti-viral immunity

KW - CD8 T cells

KW - TLR2

KW - vaccination

UR - http://www.scopus.com/inward/record.url?scp=84899441022&partnerID=8YFLogxK

U2 - 10.1038/icb.2013.102

DO - 10.1038/icb.2013.102

M3 - Article

VL - 92

SP - 377

EP - 383

JO - Immunology and Cell Biology

JF - Immunology and Cell Biology

SN - 0818-9641

IS - 4

ER -